Most scholars believe that in many different types of tumor cells, activation of wild-type P53 can make them sensitive to some chemotherapeutic drugs; while mutant P53 can specifically activate MDR-1/P-gp initiation and can increase the expression of MDR-1, MRP genes and make tumor cells produce multidrug-resistant (MDR) (Breier et al., 2013; Chen et al., 2014; Zhang et al., 2020). This evidence concerns the gene TP53 and neoplasm.